Cancer immunotherapy in second-line treatment of non-small cell lung cancer – is there a need to change the approach to the assessment of clinical benefits?
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2017, Vol 2, Issue 2
Abstract
Background: The mechanism of action distinctive for immunotherapy leads to the specific pattern of tumour response, different form the one observed with cytotoxic therapy. To enable a complete assessment of immunotherapeutic agents modified criteria for the evaluation of antitumour responses were developed, mainly on the basis of the ipilimumab trials in melanoma. Methods: We conducted a review of RCTs that assessed PD-1/PD-L1 checkpoint inhibitors in previously treated patients with NSCLC, to describe the overall survival results in comparison to the progression-free survival outcomes, as assessed with conventional RECIST and/or with modified criteria of tumour response. Results: Five RCTs were eligible. The studies were heterogeneous with respect to population characteristics and other methodological features. All of the trials showed significant OS improvement in the immunotherapy arms, with the results in the histology and PD-L1-expression subgroups consistent with ITT analyses. The OS gain was not accompanied with the evidence of PFS prolongation. The use of the modified criteria resulted in prolonged median PFS estimates in the immunotherapy-treated patients. Conclusion: Our results in second-line NSCLC population are in line with the previous findings, that the conventional RECIST criteria do not fully capture the benefit of the immunotherapy. In the routine practice the premature diagnosis of a progressive disease may result in treatment withdrawal in patients that might benefit from the continuation of the immunotherapy. Further research and the agreement on the relevant modified criteria are needed for the use in the future immunotherapy clinical trials and to inform real-world clinical decisions.
Authors and Affiliations
Anna Panasiuk, Rafał Wójcik, Małgorzata Budasz-Świderska, Marcin Kaczor
Keywords
Related Articles
- EP ID EP326205
- DOI 10.7365/JHPOR.2017.2.9
- Views 79
- Downloads 0
Optimization of approaches to the treatment of metastatic colorectal cancer wild-type gene KRAS
The results of the literature review of drug use for the treatment of metastatic colorectal cancer (mCRC) are presented. Analysis of the data showed that cetuximab (Erbitux) and panitumumab (Vectibix) are effective drugs...
Assessment of thrombocytopenia symptoms using vignettes. Preliminary report on the development and implementation of a new instrument
Objective: Our aim was to create a vignette enabling the assessment of the impact of thrombocytopenia symptoms on patients’ quality of life. Methods: The vignettes which we created are focused on thrombocytopenia sym...
Pharmaceutical Policies under Economic Crisis: The Greek case
Introduction: The purpose of this paper is to critically assess the Pharmaceutical reforms implemented in Greece before and during the economic crisis. The effects of the crisis are multiple in terms of GDP reduction, se...
Healthcare needs maps – evidence informed healthcare policy
Abstract The healthcare system in Poland suffers from some inefficiency in its organization, functioning and financing. In order to implement comprehensive change management in healthcare sector, the Polish Ministry of...
The study of the need for interprofessional collaboration in the health care system in Poland - experience of Lesław A. Paga Foundation.
Background: Interprofessional collaboration (IC) in healthcare is a process by which professionals from different disciplines collaborate to provide an integrated and cohesive approach to patient care. The Lesław A. Paga...